A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure

Phase 3

• Conditions: Hypertension

• Registration Number: JPRN-jRCT2080220304
• Lead Sponsor: ovartis Pharma K.K.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-10-03
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: Not specified
• Target Recruitment: 356

Inclusion Criteria

Inclusion criteria
- Patients with at least 65 years-old
- Patients with essential hypertension

Exclusion criteria
- Severe hypertension
- History or evidence of a secondary form of hypertension
- History of Hypertensive encephalopathy or cerebrovascular accident.

Other protocol-defined inclusion/exclusion criteria also apply

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
-Primary Outcomes: Change from baseline in average 24 hour systolic ambulatory blood pressure after 8 weeks -Secondary Outcomes: Change from baseline in average 24 hour diastolic ambulatory blood pressure after 8 weeks; Change from baseline in sitting systolic and diastolic blood pressure after 8 weeks; Change from baseline in daytime diastolic ambulatory blood pressure after 8 weeks; Change from baseline in daytime systolic ambulatory blood pressure after 8 weeks; Blood pressure control target of < 140/90 mmHg after 8 weeks